MegaRobo Raises Nearly $200 Million in Funding

The Beijing-based AI-for-science company secured the round led by investors including the Oman Investment Authority ahead of a planned Hong Kong listing.

Updated on Nov. 19, 2026 in Robotics

Bold flat-color editorial illustration of a robotic arm holding a glass sample vial over empty laboratory wells in navy and cream.
MegaRobo Technologies raised nearly $200 million from the Oman Investment Authority, CMB International and existing backers ahead of a planned Hong Kong listing. AI Illustration. Upload story photo >

Live Poll

Do you think AI-driven science companies will make everyday medicines better for people?

MegaRobo Technologies raised nearly $200 million in a funding round that included the Oman Investment Authority, CMB International, and existing investors Asia Investment Capital, Granite Asia and Sinovation Ventures. The company, founded in 2016 as an AI for Science (AI4S) firm, has raised about $600 million across multiple rounds.

Why it matters

The raise supports MegaRobo's push to automate laboratory workflows for drug screening and target discovery, serving over 1,200 pharmaceutical firms, biotech companies and academic institutions. The company is also still in the queue for a Hong Kong initial public offering filed in mid-2025.

MegaRobo's AI4S infrastructure integrates AI, scientific computing, experimental execution, data and R&D decision-making across its automated laboratory workflows. The company generates about 80% of its revenue domestically, and the report does not detail the technical performance benchmarks of its platform.

The players

MegaRobo Technologies

A Beijing-based AI-for-science company founded in 2016 that automates laboratory workflows for pharmaceutical and biotech clients.

Oman Investment Authority

The sovereign investment fund of Oman that participated in MegaRobo's current funding round.

The details

MegaRobo said the new proceeds will go toward continued investment in its core technology and expansion across Europe, North America, the Middle East and Asia. The company sees substantial overseas growth opportunities, particularly across Belt and Road markets.

Timeline

  1. June 2022: Series C round of near-$300 million co-led by Goldman Sachs Alternatives, Asia Investment Capital and Granite Asia pushed valuation past $1 billion.

  2. Mid-2025: MegaRobo filed for a Hong Kong initial public offering.

  3. November 19, 2026: MegaRobo announced the nearly $200 million funding round.

Market Landscape

MegaRobo's pending Hong Kong listing places it among mainland Chinese technology firms pursuing capital through Hong Kong exchanges. Its Belt and Road expansion plans position it against rivals seeking growth in markets across Asia and the Middle East.

For pharmaceutical and biotech clients, MegaRobo's automation could shorten drug screening and target discovery timelines. Ordinary consumers are unlikely to see direct effects unless the expanded platform reaches new products or markets.

The takeaway

Investment in AI-driven laboratory automation is increasingly drawing sovereign and cross-border capital. Companies in this space are likely to be judged on the scale of their client base and their ability to expand internationally.

Further reading

Explore more Robotics coverage to see how automation is reshaping laboratory and drug-discovery work.

Source note: This article includes information reported by DealStreetAsia.

Live Poll

Do you think AI-driven science companies will make everyday medicines better for people?